news
New data for Trulicity and Tradjenta in type 2 diabetes
Lilly has announced new findings from separate studies of Trulicity (dulaglutide) and Tradjenta (linagliptin) at the American Diabetes Association 76th Scientific Sessions.
List view / Grid view
Boehringer Ingelheim
article
Boehringer Ingelheim at ASCO: Oncology and Innovation
6 June 2016 | By Victoria White, Digital Content Producer
We recently caught up with Dr Jörg Barth, Boehringer Ingelheim, to find out more about the company’s oncology pipeline and presence at ASCO....
news
Tiotropium found to improve lung function of children with asthma
18 May 2016 | By Katie Sadler
New data has revealed tiotropium improves lung function in children who continue to experience asthma symptoms despite taking other maintenance therapies.
news
Jardiance to be investigated in chronic heart failure trials
19 April 2016 | By Victoria White, Digital Content Producer
Boehringer Ingelheim and Lilly have announced plans to conduct two trials investigating Jardiance for the treatment of people with chronic heart failure...
news
Afatinib significantly improved clinical outcomes compared to gefitinib in NSCLC trial
13 April 2016 | By Victoria White, Digital Content Producer
Results from the Phase IIb LUX-Lung 7 trial showed that afatinib significantly reduced the risk of lung cancer progression by 27% versus gefitinib...
news
Only minority of COPD patients may benefit from inhaled corticosteroids
8 April 2016 | By Victoria White, Digital Content Producer
A new study shows that levels of eosinophils can help identify patients with COPD who may and may not benefit from the addition of ICS treatment...
news
EC grants marketing authorisation to afatinib in SqCC of the lung
7 April 2016 | By Victoria White, Digital Content Producer
Afatinib is approved for the treatment of patients whose disease has progressed on or after treatment with platinum-based chemotherapy...
news
Spiriva Respimat effective regardless of allergy subtype, study finds
8 March 2016 | By Victoria White
The addition of Spiriva Respimat to other asthma maintenance therapies helps improve asthma symptom control regardless of allergy subtype...
news
AbbVie and Boehringer Ingelheim collaborate on BI 655066
7 March 2016 | By Victoria White
BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma...
news
CHMP adopts positive opinion of afatinib in SqCC
29 February 2016 | By Victoria White
The CHMP positive opinion is based on the results of the head-to-head LUX-Lung 8 trial in patients with SqCC...
news
Boehringer Ingelheim launches two initiatives to help those living with IPF
29 February 2016 | By Victoria White
Boehringer Ingelheim's new initiatives are dedicated to raising awareness of IPF, a rare disease that is frequently misdiagnosed and little understood...
news
Ofev slows disease progression in IPF and reduces risk of acute exacerbations
25 February 2016 | By Victoria White
Pooled analysis from the TOMORROW and INPULSIS trials provides further evidence that Ofev (nintedanib) significantly reduces the risk of acute exacerbations by 47% in people...
news
Praxbind (idarucizumab) reimbursed in England, Ireland and Wales
17 February 2016 | By Victoria White
Praxbind (idarucizumab) is now available to be used commercially after the Health Technology Appraisal bodies agreed that it is eligible for full reimbursment without the need for a full appraisal.
news
Boehringer Ingelheim’s Spiriva Respimat available in the US
4 February 2016 | By Victoria White
Unlike other asthma daily maintenance treatments, Spiriva Respimat is from a new class of medications in asthma known as long-acting anticholinergics...
news
NICE recommends five new therapies
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
